Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
166.3 USD | +0.88% | -0.89% | -7.92% |
02/05 | UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating | MT |
01/05 | Repligen's Q1 Adjusted Earnings, Revenue Fall | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.92% | 9.21B | |
-4.77% | 182B | |
+0.38% | 110B | |
-3.85% | 67.92B | |
+2.21% | 50.96B | |
+9.58% | 44.7B | |
+2.70% | 40.66B | |
+23.74% | 27.6B | |
+3.75% | 26.63B | |
-0.44% | 24.98B |
- Stock Market
- Equities
- RGEN Stock
- News Repligen Corporation
- Transcript : Repligen Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02